Zobrazeno 1 - 5
of 5
pro vyhledávání: '"A Jim, Nagy"'
Autor:
Vincent, Martin, A Jim, Nagy, Marina, Janelidze, Gvantsa, Giorgadze, Joe, Hirman, Roger, Cady, Lahar, Mehta, Dawn C, Buse
Publikováno v:
Clinical Therapeutics. 44:389-402
In the PROMISE-1 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-1) and PROMISE-2 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2) clinical trials, eptinezumab 100 mg and 300 mg met the primary efficacy end poi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::232bc630370f050b241cb1014802d8b1
https://doi.org/10.1016/j.clinthera.2022.01.006
https://doi.org/10.1016/j.clinthera.2022.01.006
Publikováno v:
European Journal of Neurology
Background and purpose Humanized monoclonal antibody galcanezumab, which binds to calcitonin-gene-related peptide, has shown efficacy for episodic and chronic migraine prevention. These analyses evaluated galcanezumab response for migraine headache p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::868666be2e4da038f43753fde9355ac5
https://doi.org/10.1111/ene.14102
https://doi.org/10.1111/ene.14102
Publikováno v:
Headache
Objective To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. Background Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene‐related peptide (CGRP) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4a0af7384a8c6f3bfdcd569c811bcf
https://doi.org/10.1111/head.13427
https://doi.org/10.1111/head.13427
Publikováno v:
Headache
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d77bd518d6087b8610bafb929b9bb8a
https://doi.org/10.1111/head.13514
https://doi.org/10.1111/head.13514
Publikováno v:
Headache: The Journal of Head & Face Pain; Oct2018, Vol. 58 Issue 9, p1347-1357, 11p, 2 Charts, 6 Graphs